Answers are grounded in this paper and cite their sources.
INTRODUCTION: Untreated perinatal opioid use disorder (OUD) is a major contributor to maternal and infant morbidity and mortality, worsened by an often adulterated fentanyl-dominant drug supply. Medication for OUD (MOUD) is standard of care, yet evidence guiding selection, initiation, dosing, pain management, neonatal withdrawal, breastfeeding, and postpartum continuity is evolving. AREAS COVERED: This narrative review with expert opinion synthesizes five years of literature, alongside foundational trials, on MOUD treatment across pregnancy, delivery, and the first postpartum year, prioritizing shared decision-making and trauma-responsive care. Topics include MOUD maternal dose and formulation, fentanyl-era induction, adulterant-complicated withdrawal, peripartum pain management, neonatal considerations, medication-specific breastfeeding, postpartum co-occurring mental health and MOUD access challenges, and long-term child outcomes. A PubMed, Embase, and ClinicalTrials.gov search (2020-2026) supplemented foundational sources. EXPERT OPINION: Treatment needs to center in trust, non-judgment, and shared decision-making. Extended-release buprenorphine is an emerging preferred option, especially for patients stabilized on buprenorphine, and buprenorphine-naloxone appears to be as good as, if not better than, buprenorphine alone. Withdrawal management must accommodate an increasingly adulterated drug supply, and breastfeeding is generally compatible with MOUD. Like all children, prenatally opioid-exposed children need nurturing care, developmental screening, and early intervention when indicated.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: